<DOC>
	<DOCNO>NCT00370253</DOCNO>
	<brief_summary>The purpose study determine whether noradrenalin effective safe terlipressin treatment hepatorenal syndrome</brief_summary>
	<brief_title>Noradrenalin v Terlipressin Hepatorenal Syndrome</brief_title>
	<detailed_description>Hepatorenal syndrome ( HRS ) major complication cirrhosis ; characterize functional renal failure poor prognosis . Arterial dilation key pathogenic event HRS , lead reduction effective blood volume , homeostatic activation vasoactive system renal vasoconstriction decrease renal blood flow . The clinical sign HRS vary depend clinical pattern . HRS type 1 characterize rapidly progressive renal failure ; HRS type 2 moderate stable renal failure . HRS type 1 poor short term prognosis , median survival 2 week ; patient HRS type 2 median survival 6 month . The management HRS still constitute major challenge . Liver transplantation ideal treatment , important inherent drawback , organ shortage time need perform transplant , long consent survival patient . The management HRS focus improve renal function , thus extend patient survival allow performance liver transplant . In last year , remarkable result obtain use vasoconstrictor drug . By improve effective blood volume , vasoconstrictor induce suppression homeostatic vasoactive system increase renal blood flow glomerular filtration rate.Among vasoconstrictor , terlipressin , V1 vasopressin agonist , currently best efficacy pedigree . However , expensive available many country , include North America . More recently , suggest alpha-adrenergic drug noradrenalin midodrine may also effective HRS . Noradrenalin would potential advantage wider availability low cost . The current prospective randomize study undertaken ass efficacy safety noradrenalin v terlipressin patient HRS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>Hepatorenal syndrome Age : 1875 year Informed write consent Multinodular hepatocellular carcinoma ( 3 nodule ) Portal vein thrombosis Ongoing bacterial infection Ongoing recent ( less one week ) bleeding Cardiopulmonary failure Coronary artery disease Peripheral artery disease Arterial hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>hepatorenal syndrome</keyword>
	<keyword>ascites</keyword>
	<keyword>portal hypertension</keyword>
	<keyword>cirrhosis</keyword>
</DOC>